Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia
Details
Publication Year 2022-07-07,Volume 14,Issue #7,Page e15203
Journal Title
EMBO Molecular Medicine
Publication Type
Research article
Abstract
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential metabolic precursors for nucleic acids, glycoproteins, and phospholipids. DHODH inhibitors (DHODHi) are clinically used for autoimmune diseases and are emerging as a novel class of anticancer agents, especially in acute myeloid leukemia (AML) where pyrimidine starvation was recently shown to reverse the characteristic differentiation block in AML cells. Herein, we show that DHODH blockade rapidly shuts down protein translation in leukemic stem cells (LSCs) and has potent and selective activity against multiple AML subtypes. Moreover, we find that ablation of CDK5, a gene that is recurrently deleted in AML and related disorders, increases the sensitivity of AML cells to DHODHi. Our studies provide important molecular insights and identify a potential biomarker for an emerging strategy to target AML.
Keywords
Dihydroorotate Dehydrogenase; Enzyme Inhibitors/pharmacology; Humans; *Leukemia, Myeloid, Acute; *Oxidoreductases Acting on CH-CH Group Donors/metabolism; Protein Biosynthesis; Pyrimidines/pharmacology; Dhodh; acute myeloid leukemia; leukemic stem cells; protein translation
Department(s)
Laboratory Research
PubMed ID
35514210
Open Access at Publisher's Site
https://doi.org/10.15252/emmm.202115203
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-04-11 03:02:36
Last Modified: 2025-04-11 03:05:16

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙